Paradoxical severe decrease in high-density lipoprotein cholesterol due to rosiglitazone-fenofibrate interaction

Endocrine Practice

Volumn 16, Issue 3, 2010, Pages 382-388

  Schwing, William ^a   Hustak, Leighanne ^a   Taylor, Harris C ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B100; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ROSIGLITAZONE; SIMVASTATIN; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTILIPEMIC AGENT;

AGED; ARTICLE; BEDTIME DOSAGE; CASE REPORT; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG WITHDRAWAL; HUMAN; HYPERLIPIDEMIA; MALE; MEDLINE; NON INSULIN DEPENDENT DIABETES MELLITUS; PARADOXICAL DRUG REACTION; PROSPECTIVE STUDY; SIDE EFFECT; DRUG INTERACTION; METABOLISM;

AGED; ANTILIPEMIC AGENTS; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; DRUG INTERACTIONS; HUMANS; MALE; PROCETOFEN; PROSPECTIVE STUDIES; THIAZOLIDINEDIONES;

EID: 77956624132     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP09307.OR     Document Type: Article

References (23)

1. Seber S, Ucak S, Basat O, Altuntas Y. The effect of dual PPAR alpha/gamma stimulation with combination of rosiglitazone and fenofibrate on metabolic parameters in type 2 diabetic patients. Diabetes Res Clin Pract. 2006;71:52-58. (Pubitemid 41821143)
2. Magee G, Sharpe PC. Paradoxical decreases in high-density lipoprotein cholesterol with fenofibrate: A quite common phenomenon. J Clin Pathol. 2009;62:250-253.
3. Alvarez CA, Russell NM, Edwards KL, et al. Combination thiazolidinedione and fibrate effect on high-density lipoprotein cholesterol (HDL-C) concentration in a Veterans Affairs patient population. J Clin Lipidol. 2008;2:447-452.
4. Venero CD, Thompson PD, Fernandez AB. Reduced high-density lipoprotein cholesterol in patients receiving rosiglitazone and fenofibrate. Am J Med. 2008;121:e3-e4.
5. Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene, AM; PROactive Investigators. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: Results from the PROactive (PROactive 05) Study. J Am Coll Cardiol. 2007;49:1772-1780. (Pubitemid 46629127)
6. Forcheron F, Cachefo A, Thevenon S, Pinteur C, Beylot M. Mechanisms of the triglyceride- and cholesterol-lowering effect of fenofibrate in hyperlipidemic type 2 diabetic patients. Diabetes. 2002;51:3486-3491. (Pubitemid 35403454)
7. Horn JR, Hansten PD, Chan LN. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother. 2007;41:674-680. (Pubitemid 46625492)
8. Chinetti G, Lestavel S, Fruchart JC, Clavey V, Staels B. Peroxisome proliferator-activated receptor alpha reduces cholesterol esterification in macrophages. Circ Res. 2003;92:212-217. (Pubitemid 36254277)
9. Ruan XZ, Moorhead JF, Fernando R, Wheeler DC, Powis SH, Varghese Z. PPAR agonists protect mesangial cells from interleukin 1beta-induced intracellular lipid accumulation by activating the ABCA1 cholesterol efflux pathway. J Am Soc Nephrol. 2003;14:593-600. (Pubitemid 36246002)
10. Chinetti G, Lestavel S, Bocher V, et al. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med. 2001;7:53-58. (Pubitemid 32095642)
11. Bocher V, Pineda-Torra I, Fruchart JC, Staels B. PPARs: Transcription factors controlling lipid and lipoprotein metabolism. Ann N Y Acad Sci. 2002;967:7-18. (Pubitemid 34721888)
12. Sarker A, Semple RK, Dinneen SF, O'Rahilly S, Martin SC. Severe hypo-alpha-lipoproteinemia during treatment with rosiglitazone. Diabetes Care. 2004;27:2577-2580.
13. Savage RL, Kiuru A. Thiazolidinediones and lowered HDL cholesterol. Diabetes Care. 2005;28:2329-30. (Pubitemid 41242493)
14. Ebcioglu Z, Morgan J, Carey C, Capuzzi D. Paradoxical lowering of high-density lipoprotein cholesterol level in 2 patients receiving fenofibrate and a thiazolidinedione. Ann Intern Med. 2003;139:W80.
15. Normén, L, Frohlich J, Montaner J, Harris M., Elliott T, Bondy G. Combination therapy with fenofibrate and rosiglitazone paradoxically lowers serum HDL cholesterol. Diabetes Care. 2004;27:2241-2242. (Pubitemid 39167192)
16. Senba H, Kawano M, Kawakami M. Severe decrease in serum HDL-cholesterol during combination therapy of bezafibrate and pioglitazone. J Atheroscler Thromb. 2006;13:263-264.
17. Willcox D. Rosiglitazone (Avandia): Decreased high-density lipoprotein cholesterol levels. Canadian Adverse Reaction Newsletter. 2005;15:3.
18. Gutschi LM, Malcolm JC, Favreau CM, Ooi TC. Paradoxically decreased HDL-cholesterol levels associated with rosiglitazone therapy. Ann Pharmacother. 2006;40:1672-1676. (Pubitemid 44330213)
19. Shetty C, Balasubramani M, Capps N, Milles J, Ramachandran S. Paradoxical HDL-C reduction during rosiglitazone and fibrate treatment. Diabet Med. 2007;24:94-97. (Pubitemid 46103078)
20. Glaysher J, Van Heyningen C. Paradoxical decrease in high-density lipoprotein-cholesterol associated with statin and fenofibrate combination therapy. Br J Diabetes Vasc Dis. 2007;7:295-297.
21. Keidar S, Guttmann H, Stam T, Fishman I, Shapira C. High incidence of reduced plasma HDL cholesterol in diabetic patients treated with rosiglitazone and fibrate. Pharmacoepidemiol Drug Saf. 2007;16:1192-1194. (Pubitemid 350120643)
22. Beghin L, Capps N, Duhal N, Davies J, Staels B, Luc G. Metabolism of apolipoproteins AI and AII in a patient with paradoxical reduction in high-density lipoprotein due to ciprofibrate. Ann Clin Biochem. 1999;36:523-525. (Pubitemid 29338575)
23. Staels B, Auwerx J. Regulation of apo A-1 gene expression by fibrates. Atherosclerosis. 1998;137(Suppl):S19-S23. (Pubitemid 28294203)